| Gene | [NTRK1](/genes/ntrk1) (aka TRKA) |
|---|---|
| UniProt | P04629 |
| PDB Structures | 1WWA, 2CT0, 4GT4 |
| Molecular Weight | ~140 kDa (full-length), ~85 kDa (mature, after processing) |
| Protein Length | 796 amino acids (full-length) |
| Subcellular Localization | Plasma membrane, endosomes, retrograde signaling endosomes |
| Protein Family | Receptor tyrosine kinase (RTK) family, Trk family |
| Chromosomal Location | 1q21-q22 |
| Ligands | NGF (Nerve Growth Factor), NT-3 (cross-reactivity at low affinity) |
TrkA (Tropomyosin Receptor Kinase A) is a high-affinity receptor tyrosine kinase for nerve growth factor (NGF), encoded by the NTRK1 gene on chromosome 1q21-22. TrkA is a member of the Trk receptor tyrosine kinase family (TrkA, TrkB, TrkC) that mediates the cellular effects of neurotrophins — a class of growth factors essential for neuronal development, survival, and maintenance[1].
In the adult brain, TrkA is predominantly expressed in basal forebrain cholinergic neurons (BFCNs), which are the primary source of acetylcholine to the hippocampus and neocortex. These cholinergic neurons undergo progressive degeneration in Alzheimer's disease (AD), and the NGF/TrkA pathway is widely recognized as a key survival signaling axis that fails in AD[2][3].
The NGF/TrkA signaling cascade activates three major downstream pathways — PI3K/Akt, MAPK/ERK, and PLCγ1 — that promote neuronal survival, synaptic plasticity, and gene expression. Therapeutic strategies targeting TrkA aim to preserve or enhance this signaling to protect cholinergic neurons from degeneration[4].
TrkA is a type I transmembrane receptor with distinct extracellular and intracellular domains:
| Region | Residues | Features |
|---|---|---|
| Signal peptide | 1-33 | N-terminal secretory signal |
| Extracellular domain | 34-407 | Ligand binding, cysteine-rich clusters |
| Transmembrane helix | 408-428 | Single-pass alpha-helix |
| Juxtaplasma domain | 429-445 | Dimerization interface |
| Kinase domain | 446-736 | Tyrosine kinase activity |
| C-terminal tail | 737-796 | Signaling motifs, regulatory sites |
The extracellular region contains features critical for ligand recognition[5]:
The intracellular kinase domain contains:
NGF binding triggers TrkA activation through[6]:
TrkA activates three major intracellular signaling cascades[1:1]:
The PI3K/Akt pathway is the primary pro-survival signaling arm of TrkA[7]:
The MAPK pathway promotes neuronal differentiation and survival gene expression:
PLCγ1 generates second messengers for synaptic plasticity:
TrkA is essential for the development, maintenance, and function of basal forebrain cholinergic neurons (BFCNs)[8]:
Anatomical Location:
Functions:
The NGF/TrkA axis is one of the most studied therapeutic targets in AD[2:1][9]:
Evidence of Dysfunction:
Pathological Links:
Neurotrophic Hypothesis: The "trophic support" hypothesis posits that AD cholinergic neurons lose access to sufficient NGF/TrkA signaling, making them vulnerable to amyloid and tau pathology[3:1].
A critical feature of TrkA signaling is retrograde axonal transport:
In AD, axonal transport deficits disrupt this retrograde signaling, contributing to cholinergic dysfunction.
Multiple approaches target the NGF/TrkA axis[4:1][11]:
| Approach | Agent | Status | Mechanism |
|---|---|---|---|
| NGF infusion | Recombinant NGF | Phase 1/2 trials | Direct TrkA activation |
| NGF gene therapy | AAV-NGF | Preclinical | Sustained NGF expression |
| TrkA agonists | 7,8-DHF, GNF-583 | Preclinical | Small molecule activation |
| mimetic peptides | P75^NTR ligands | Research | p75^NTR modulation |
| cell-based delivery | NGF-secreting cells | Preclinical | Localized NGF delivery |
Delivery: NGF does not cross the blood-brain barrier (BBB); requires direct CNS administration or gene therapy.
Side effects: NGF causes pain (via peripheral TrkA in nociceptors), weight loss, and sprouting of sympathetic neurons.
Tropomyosin mimetics: Small molecules that mimic NGF's TrkA-binding activity without the BBB limitation are under development.
7,8-Dihydroxyflavone (7,8-DHF): A natural TrkB agonist with some TrkA activity. Multiple preclinical studies show cognitive benefits in AD models.
GNF-583: A selective TrkA agonist with better BBB penetration than NGF.
** Antibody-based agonists**: Agonistic anti-TrkA antibodies are being explored to avoid p75^NTR-mediated side effects.
TrkA (NTRK1) is a receptor tyrosine kinase that mediates the pro-survival and differentiation effects of NGF on neurons, particularly basal forebrain cholinergic neurons. TrkA activation triggers PI3K/Akt, MAPK/ERK, and PLCγ1 signaling cascades that promote neuronal survival, synaptic plasticity, and gene expression. In Alzheimer's disease, impaired NGF/TrkA signaling contributes to cholinergic neuron degeneration and cognitive decline. Therapeutic strategies aim to enhance TrkA signaling through NGF administration, gene therapy, or small molecule agonists.
Patapoutian A, et al. Trk receptors: mediators of neurotrophin signaling. Nat Neurosci. 2001. ↩︎ ↩︎
Cuello AC, et al. NGF and TrkA in Alzheimer's disease. Trends Neurosci. 2003. ↩︎ ↩︎
Cuello AC. NGF and TrkA: 25 years of progress in Alzheimer's disease. Brain Res Bull. 2020. ↩︎ ↩︎
Sebbe R, et al. TrkA agonists for neurodegenerative disease. Neuropharmacology. 2022. ↩︎ ↩︎
Barbacci E, et al. NGF induces TrkA receptor autophosphorylation. J Biol Chem. 1995. ↩︎
Kaplan DR, et al. Trk signal transduction in neurons. Neurochem Res. 1998. ↩︎
Fahnestock M, et al. NGF and BDNF in Alzheimer's disease. Int J Dev Neurosci. 2001. ↩︎
Huang EJ, et al. TrkA in the basal forebrain cholinergic neurons. J Neurosci. 2019. ↩︎
Salehi AH, et al. TrkA depletion and apoptosis in Alzheimer's disease. Mol Cell Neurosci. 2000. ↩︎
Ginsberg SD, et al. TrkA in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging. 2006. ↩︎
Longo FM, et al. Small molecule TrkA agonists for Alzheimer's disease. Alzheimers Dement. 2020. ↩︎